drugset / Trial / NCT00746681

Investigation of Tolterodine, Pregabalin and a Tolterodine - Pregabalin Combination for the Treatment of Overactive Bladder

NCT00746681

Phase 2 Completed 188 enrolled Pfizer
RandomizedCrossoverTriple-blindTreatment

Summary

Tolterodine is approved for use in the treatment of overactive bladder (OAB). The study is designed to a investigate whether pregabalin may have efficacy in OAB and whether the efficacy is altered when it is combined with tolterodine.

Timeline

Start
2005-12
Primary completion
Completion
2006-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Pregabalin Small molecule 75 mg Oral
Subject Pregabalin Small molecule 150 mg Oral
Subject Tolterodine Small molecule 2 mg Oral
Subject Tolterodine Small molecule 4 mg Oral

Indications